Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

BACE1 partial deletion induces synaptic plasticity deficit in adult mice.

Tytuł:
BACE1 partial deletion induces synaptic plasticity deficit in adult mice.
Autorzy:
Lombardo S; Alzheimer's Disease Research Laboratory, Department of Neuroscience, Tufts University School of Medicine, Boston, Massachusetts, 02111, USA.; Department of Neuroscience, Tufts University School of Medicine, Boston, Massachusetts, 02111, USA.
Chiacchiaretta M; Department of Neuroscience, Tufts University School of Medicine, Boston, Massachusetts, 02111, USA.
Tarr A; Circuits and Behaviour Core, Center for Neuroscience Research, Tufts University School of Medicine, Boston, Massachusetts, 02111, USA.
Kim W; Alzheimer's Disease Research Laboratory, Department of Neuroscience, Tufts University School of Medicine, Boston, Massachusetts, 02111, USA.; Department of Neuroscience, Tufts University School of Medicine, Boston, Massachusetts, 02111, USA.
Cao T; Alzheimer's Disease Research Laboratory, Department of Neuroscience, Tufts University School of Medicine, Boston, Massachusetts, 02111, USA.; Department of Neuroscience, Tufts University School of Medicine, Boston, Massachusetts, 02111, USA.
Sigal G; Alzheimer's Disease Research Laboratory, Department of Neuroscience, Tufts University School of Medicine, Boston, Massachusetts, 02111, USA.; Department of Neuroscience, Tufts University School of Medicine, Boston, Massachusetts, 02111, USA.
Rosahl TW; External In Vivo Pharmacology, Merck & Co. Inc., Kenilworth, NJ, 07033, USA.
Xia W; Geriatric Research, Education and Clinic Center, Bedford Veterans Affairs Medical Center, Bedford, MA, 01730, USA.; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, 02118, USA.
Haydon PG; Department of Neuroscience, Tufts University School of Medicine, Boston, Massachusetts, 02111, USA.
Kennedy ME; Department of Neuroscience, Merck & Co. Inc, Boston, MA, 02115, USA.
Tesco G; Alzheimer's Disease Research Laboratory, Department of Neuroscience, Tufts University School of Medicine, Boston, Massachusetts, 02111, USA. .; Department of Neuroscience, Tufts University School of Medicine, Boston, Massachusetts, 02111, USA. .
Źródło:
Scientific reports [Sci Rep] 2019 Dec 27; Vol. 9 (1), pp. 19877. Date of Electronic Publication: 2019 Dec 27.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
Język:
English
Imprint Name(s):
Original Publication: London : Nature Publishing Group, copyright 2011-
MeSH Terms:
CA1 Region, Hippocampal*/enzymology
CA1 Region, Hippocampal*/pathology
Cerebral Cortex*/enzymology
Cerebral Cortex*/pathology
Gene Deletion*
Amyloid Precursor Protein Secretases/*deficiency
Aspartic Acid Endopeptidases/*deficiency
Axon Guidance/*genetics
Neuronal Plasticity/*genetics
Amyloid Precursor Protein Secretases/metabolism ; Amyloid beta-Peptides/genetics ; Amyloid beta-Peptides/metabolism ; Animals ; Aspartic Acid Endopeptidases/metabolism ; Mice ; Mice, Knockout
References:
Mol Neurodegener. 2011 Dec 28;6:88. (PMID: 22204380)
Nature. 1999 Dec 2;402(6761):537-40. (PMID: 10591214)
N Engl J Med. 2019 Apr 11;380(15):1483-1485. (PMID: 30970197)
J Biol Chem. 2012 Nov 9;287(46):38408-25. (PMID: 22988240)
Nat Methods. 2012 Jun 28;9(7):676-82. (PMID: 22743772)
Neural Regen Res. 2017 Oct;12(10):1565-1574. (PMID: 29171411)
Alzheimers Res Ther. 2014 Dec 24;6(9):89. (PMID: 25621019)
Front Aging Neurosci. 2018 Jul 26;10:229. (PMID: 30093858)
J Neurochem. 2006 Dec;99(6):1555-63. (PMID: 17083447)
Neuron. 2004 Jan 8;41(1):27-33. (PMID: 14715132)
CNS Drugs. 2019 Mar;33(3):251-263. (PMID: 30830576)
J Exp Med. 2018 Mar 5;215(3):927-940. (PMID: 29444819)
PLoS One. 2016 May 18;11(5):e0155799. (PMID: 27192432)
Cell Rep. 2015 Sep 1;12(9):1367-76. (PMID: 26299962)
Nature. 2007 Feb 8;445(7128):661-5. (PMID: 17251932)
Nature. 1999 Dec 2;402(6761):533-7. (PMID: 10591213)
Mol Cell Neurosci. 1999 Dec;14(6):419-27. (PMID: 10656250)
Genesis. 2013 Feb;51(2):120-7. (PMID: 23109354)
N Engl J Med. 2018 May 3;378(18):1691-1703. (PMID: 29719179)
Science. 1999 Oct 22;286(5440):735-41. (PMID: 10531052)
Nature. 2012 Aug 2;488(7409):96-9. (PMID: 22801501)
Cell Rep. 2013 Jul 11;4(1):40-9. (PMID: 23831026)
J Neurosci. 2005 Dec 14;25(50):11693-709. (PMID: 16354928)
Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5585-90. (PMID: 18385378)
J Biol Chem. 2014 Nov 7;289(45):30990-1000. (PMID: 25253696)
Bioorg Med Chem Lett. 2019 Mar 15;29(6):761-777. (PMID: 30709653)
Mol Neurodegener. 2016 Oct 5;11(1):67. (PMID: 27716410)
Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1456-60. (PMID: 10677483)
J Neurosci. 2008 Aug 27;28(35):8677-81. (PMID: 18753368)
FASEB J. 2008 Aug;22(8):2970-80. (PMID: 18413858)
Sci Transl Med. 2018 Sep 19;10(459):. (PMID: 30232227)
Nat Neurosci. 2016 Jan;19(1):55-64. (PMID: 26642089)
Front Mol Neurosci. 2017 Jan 05;9:159. (PMID: 28105004)
Bio Protoc. 2018 Jan 20;8(2):. (PMID: 29552595)
Neurobiol Dis. 2007 Apr;26(1):134-45. (PMID: 17258906)
J Biol Chem. 2005 Apr 29;280(17):17020-6. (PMID: 15711015)
Sci Transl Med. 2016 Nov 2;8(363):363ra150. (PMID: 27807285)
Biol Psychiatry. 2018 Oct 1;84(7):478-487. (PMID: 29945719)
J Biol Chem. 2010 Jul 2;285(27):20664-74. (PMID: 20427278)
Mol Neurodegener. 2018 Feb 2;13(1):6. (PMID: 29391027)
EMBO J. 2012 Jun 22;31(14):3157-68. (PMID: 22728825)
N Engl J Med. 2019 Apr 11;380(15):1408-1420. (PMID: 30970186)
Lancet Neurol. 2014 Mar;13(3):319-29. (PMID: 24556009)
Mol Cell Biol. 2002 Nov;22(22):7967-81. (PMID: 12391163)
Biol Psychiatry. 2015 Apr 15;77(8):729-39. (PMID: 25599931)
Nat Neurosci. 2006 Dec;9(12):1520-5. (PMID: 17099708)
Neuron. 2007 Nov 21;56(4):621-39. (PMID: 18031681)
Acta Neuropathol. 2013 Sep;126(3):329-52. (PMID: 23820808)
Science. 2006 Oct 27;314(5799):664-6. (PMID: 16990514)
Ann Neurol. 2017 Jul;82(1):128-132. (PMID: 28556232)
Science. 2000 Oct 6;290(5489):150-3. (PMID: 11021803)
Grant Information:
R01AG025952 International U.S. Department of Health & Human Services | NIH | Center for Scientific Review (NIH Center for Scientific Review); R01 AG025952 United States AG NIA NIH HHS; R01 NS092497 United States NS NINDS NIH HHS; P30 NS045776 United States NS NINDS NIH HHS; R01NS092497 International U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
Substance Nomenclature:
0 (Amyloid beta-Peptides)
EC 3.4.- (Amyloid Precursor Protein Secretases)
EC 3.4.23.- (Aspartic Acid Endopeptidases)
EC 3.4.23.46 (Bace1 protein, mouse)
Entry Date(s):
Date Created: 20191229 Date Completed: 20201105 Latest Revision: 20210110
Update Code:
20240104
PubMed Central ID:
PMC6934620
DOI:
10.1038/s41598-019-56329-7
PMID:
31882662
Czasopismo naukowe
BACE1 is the first enzyme involved in APP processing, thus it is a strong therapeutic target candidate for Alzheimer's disease. The observation of deleterious phenotypes in BACE1 Knock-out (KO) mouse models (germline and conditional) raised some concerns on the safety and tolerability of BACE1 inhibition. Here, we have employed a tamoxifen inducible BACE1 conditional Knock-out (cKO) mouse model to achieve a controlled partial depletion of BACE1 in adult mice. Biochemical and behavioural characterization was performed at two time points: 4-5 months (young mice) and 12-13 months (aged mice). A ~50% to ~70% BACE1 protein reduction in hippocampus and cortex, respectively, induced a significant reduction of BACE1 substrates processing and decrease of Aβx-40 levels at both ages. Hippocampal axonal guidance and peripheral nerve myelination were not affected. Aged mice displayed a CA1 long-term potentiation (LTP) deficit that was not associated with memory impairment. Our findings indicate that numerous phenotypes observed in germline BACE1 KO reflect a fundamental role of BACE1 during development while other phenotypes, observed in adult cKO, may be absent when partially rather than completely deleting BACE1. However, we demonstrated that partial depletion of BACE1 still induces CA1 LTP impairment, supporting a role of BACE1 in synaptic plasticity in adulthood.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies